Lesedauer von 5 Min.
10. März 2026
Lesedauer von 4 Min.
24. November 2025
Lesedauer von 5 Min.
27. März 2026
Artikel
Hepatitis C elimination in the U.S. is within reach—if we do three things: expand point‑of‑care testing, scale treatment access, and unify stakeholders for coordinated action, according to health economists Louis Garrison, Ph.D. and Bruce Wang, Ph.D.
In a Viewpoint paper in JAMA Health Forum, the economists detail progress toward HCV elimination, including why "single-step HCV diagnosis is widely seen as a critical component of an HCV elimination program"1 and why U.S. policy makers should support the Cure Hepatitis C Act of 2025 (S.1941).
At Cepheid, we’re proud to support HCV elimination efforts by offering the Xpert® HCV test, which provides point‑of‑care molecular detection to help expand access to diagnosis.
Read the full paper JAMA Health Forum.
IVD. In-vitro-Diagnostikum. Eventuell nicht in allen Ländern erhältlich.
1 Garrison LP, Wang BCM. Stakeholder Engagement for Hepatitis C Virus Elimination. JAMA Health Forum. 2026;7(1):e256433. doi:10:1001/jamahealthforum.2025:6433
MEHR